The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer

摘要: Advanced-stage epithelial ovarian cancer is generally managed with cytoreductive surgery and chemotherapy consisting of carboplatin paclitaxel, achieving clinical complete remission in the majority patients. However, most tumors recur, are associated progressive resistance. Techniques to optimize have included intraperitoneal administration weekly scheduling paclitaxel. Efforts improve on long-term results primary therapy through addition a third cytotoxic agent not been successful, including extended maintenance, as well strategies overcome Limited data emerging from phase III trials using bevacizumab suggest some advantage progression-free survival, particularly maintenance setting, further awaited. At present, paclitaxel remains well-tolerated standard regimen, option dosing, delivery neoadjuvant selected Emerging biological paradigms will hopefully contribute individualized treatment options future.